Goldman Sachs Group Inc Celularity Inc Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$0.42 - $0.81 $43,252 - $83,416	102,983 Added 309.59%	136,247 $72,000
Q2 2023 Aug 14, 2023	BUY	$0.42 - $0.81 $43,252 - $83,416	102,983 Added 309.59%	136,247 $72,000
Q1 2023 May 14, 2024	SELL	$0.56 - $1.15 $10,099 - $20,739	-18,034 Reduced 35.16%	33,264 $20,000
Q1 2023 May 11, 2023	SELL	$0.56 - $1.15 $10,099 - $20,739	-18,034 Reduced 35.16%	33,264 $20,000
Q4 2022 May 14, 2024	BUY	$1.08 - $2.35 $23,680 - $51,526	21,926 Added 74.65%	51,298 $66,000
Q4 2022 Feb 13, 2023	BUY	$1.08 - $2.35 $23,680 - $51,526	21,926 Added 74.65%	51,298 $66,000
Q3 2022 May 14, 2024	BUY	$0.43 - $4.31 $12,629 - $126,593	29,372 New	29,372 $68,000
Q3 2022 Nov 10, 2022	BUY	$0.43 - $4.31 $12,629 - $126,593	29,372 New	29,372 $67,000
Q2 2022 Aug 15, 2022	SELL	$2.81 - $12.91 $58,417 - $268,385	-20,789 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.81 - $9.79 $79,206 - $203,524	20,789 New	20,789 $181,000

23.6M

Ticker CELU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,424,000
Market Cap $296M
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.